Moderna Is Testing a New Version of Its COVID-19 Vaccine That Wouldn ’t Require Ultra-Cold Storage

As safety concerns over COVID-19 vaccines from AstraZeneca and Johnson&Johnson–Janssen have led to disruptions in the inoculation efforts of numerous countries relying on those shots, companies like Moderna are attempting to fill the resulting gaps. The Massachusetts-based biotech company announced on April 29 that it is investing billions to boost manufacturing facilities in Switzerland, Spain and the U.S., building enough capacity to produce up to 3 billion doses of its mRNA-based vaccine through 2022. The company’s vaccine technology differs from that of AstraZeneca and J&J, which both use an adenovirus to deliver COVID-19 virus genes to the immune system—and which both have been have been associated with serious, life-threatening—albeit very rare—blood clots. Stephane Bancel, CEO of Moderna, says that some of the wealthier, developed countries are eager to up their orders of the mRNA vaccines (which include both the Moderna shot and one produced by Pfizer/BioNTech). “In the last month or so, in the discussions we have had with heads of state, prime ministers, presidents of countries and health ministers, when governments look at efficacy, safety, manufacturing scalability, and the speed to the next generation of vaccines, what we are hearing loud and clear is that mRNA is the best for the problem at hand,” says Bancel. “And governments around the world want more and more mRNA product.” To meet that need, and the need...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news

Related Links:

In this study, we investigated a COVID-19 cohort in Shanghai, China. We screened viruses include Human parainfluenza virus 1, Human parainfluenza virus 2, Human parainfluenza virus 3, Human parainfluenza virus4, Influenza A virus, Influenza B virus, Human rhinovirus, Human metapneumovirus, Human respiratory syncytial virus, Human Bocavirus, Human adenovirus, Human Coronavirus 229E, Human Coronavirus NL63, Human Coronavirus HKU1, Human Coronavirus OC43; bacteria include Pseudomonas aeruginosa, Moraxella catarrhalis, Mycobacterium tuberculosis, Legionella pneumophila, Group A Streptococcus, Haemophilus influenza, Staphylococ...
Source: Journal of Infection - Category: Infectious Diseases Authors: Tags: Letter to the Editor Source Type: research
(Penn State) A researcher in Penn State's College of Agricultural Sciences is part of a team of scientists working to develop a unique COVID-19 vaccine that uses a bovine adenovirus as a safe and effective delivery vehicle. With support from a nearly $3.9 million grant from the National Institutes of Health, the team aims to create a vaccine that will protect all segments of the population, especially older adults.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
Source: Infection and Drug Resistance - Category: Infectious Diseases Tags: Infection and Drug Resistance Source Type: research
Condition:   Adenovirus Type-5 Vectored COVID-19 Vaccine Intervention:   Biological: Adenovirus Type-5 Vectored COVID-19 Vaccine Sponsor:   Jiangsu Province Centers for Disease Control and Prevention Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/). PMID: 32991819 [PubMed - as supplied by publisher]
Source: American Journal of Respiratory Cell and Molecular Biology - Category: Molecular Biology Authors: Tags: Am J Respir Cell Mol Biol Source Type: research
Condition:   COVID-19 Interventions:   Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector);   Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo Sponsors:   CanSino Biologics Inc.;   Beijing Institute of Biotechnology;   Jiangsu Province Centers for Disease Control and Prevention Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins. Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Magazine Source Type: news
Janssen’s lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, prevented severe clinical disease in Syrian golden hamsters, upon challenge with SARS-CoV-2, the virus that causes COVID-19 in people. The data, published today in Nature Medicine, demonstrated that the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited an immune response as demonstrated by “neutralizing antibodies” and prevented severe clinical disease – including weight loss, pneumonia and mortality – in Syrian golden hamsters upon challenge.This publication follows Johnson &...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
As the world reels from illnesses and deaths due to COVID-19, the race is on for a safe, effective, long-lasting vaccine to help the body block the novel coronavirus SARS-CoV-2. The three vaccine approaches discussed here are among the first to be tested clinically in the United States. How vaccines induce immunity: The starting line In 1796, in a pastoral corner of England, and during a far more feudal and ethically less enlightened time, Edward Jenner, an English country surgeon, inoculated James Phipps, his gardener’s eight-year-old son, with cowpox pustules obtained from the arm of a milkmaid. It was widely belie...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Coronavirus and COVID-19 Health Infectious diseases Vaccines Source Type: blogs
Discussions with the FDA are ongoing to define the required data set for filing Janssen’s Ebola vaccine regimen under the FDA’s Animal Rule licensure pathway. About Janssen’s Ebola Vaccine Regimen The Janssen investigational preventive Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo) utilizes a viral vector strategy in which viruses – in this case adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) – are genetically modified so that they cannot replicate in human cells. In addition, these vectors are modified to safely carry the genetic code of an Ebola virus protein in order...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Adenoviruses | African Health | AstraZeneca | Biotechnology | COVID-19 | Genetics | Health | International Medicine & Public Health | Pfizer | Respiratory Medicine | South Africa Health | Spain Health | Study | Switzerland Health | Vaccines | Veterinary Vaccinations